NEW YORK, May 19, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, today announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. AMR-001 is the Company's most clinically advanced product candidate in its CD34 Cell Program and is being developed to treat damaged heat muscle following a heart attack. The European Patent Office has notified the Company that it has granted patent numbers 1951864 and 2441461 for "Compositions and Methods of Vascular Injury Repair." These represent NeoStem's first granted European patents for its CD34 Cell Program and bring the Program's total worldwide patent coverage to 16 granted and allowed patents. "We are pleased to be building our international patent portfolio in the European Union and other geographic locations," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "We hope that laying this foundation now will support partnering activities once data from our Phase 2 PreSERVE clinical trial for AMR-001 becomes available later this year." The continued expansion of the Company's intellectual property portfolio both domestically and internationally expands the commercial possibilities for its CD34 Cell Program, should any of these products in development receive regulatory approval. In the past year, NeoStem has announced expansion of its patent protection for its CD34 Cell Program in the U.S. and around the globe, including Japan, Canada, Russia, Malaysia, the Philippines, and now the European Union. Heart attacks and cardiovascular disease are significant threats to public health in many countries, not just the U.S. If approved by the FDA and other worldwide regulatory agencies, AMR-001 could address significant unmet medical needs in the treatment of cardiovascular disease around the world.